MYCOPHENILIC ACID and PRODUCT USE IN UNAPPROVED INDICATION

733 reports of this reaction

2.2% of all MYCOPHENILIC ACID reports

#6 most reported adverse reaction

Overview

PRODUCT USE IN UNAPPROVED INDICATION is the #6 most commonly reported adverse reaction for MYCOPHENILIC ACID, manufactured by Accord Healthcare Inc.. There are 733 FDA adverse event reports linking MYCOPHENILIC ACID to PRODUCT USE IN UNAPPROVED INDICATION. This represents approximately 2.2% of all 32,957 adverse event reports for this drug.

Patients taking MYCOPHENILIC ACID who experience product use in unapproved indication should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

PRODUCT USE IN UNAPPROVED INDICATION733 of 32,957 reports

PRODUCT USE IN UNAPPROVED INDICATION is a less commonly reported adverse event for MYCOPHENILIC ACID, but still significant enough to appear in the safety profile.

Other Side Effects of MYCOPHENILIC ACID

In addition to product use in unapproved indication, the following adverse reactions have been reported for MYCOPHENILIC ACID:

Other Drugs Associated with PRODUCT USE IN UNAPPROVED INDICATION

The following drugs have also been linked to product use in unapproved indication in FDA adverse event reports:

5% LIDOCAINEACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDEACETAMINOPHEN, ASPIRIN, AND CAFFEINEACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINEACETAMINOPHEN, CAFFEINEACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, AND PHENYLEPHRINE HYDROCHLORIDEACETAMINOPHEN, DEXTROMETHORPHAN HBRACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDEACETAZOLAMIDEADAPALENEADENOSINEALBENDAZOLEALLOPURINOL SODIUMAMIKACINAMIODARONE HYDROCHLORIDEAMPHOTERICIN BAMPICILLINAMPICILLIN SODIUMANTI THYMOCYTE GLOBULIN (RABBIT)ARIPIPRAZOLE

Frequently Asked Questions

Does MYCOPHENILIC ACID cause PRODUCT USE IN UNAPPROVED INDICATION?

PRODUCT USE IN UNAPPROVED INDICATION has been reported as an adverse event in 733 FDA reports for MYCOPHENILIC ACID. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is PRODUCT USE IN UNAPPROVED INDICATION with MYCOPHENILIC ACID?

PRODUCT USE IN UNAPPROVED INDICATION accounts for approximately 2.2% of all adverse event reports for MYCOPHENILIC ACID, making it a notable side effect.

What should I do if I experience PRODUCT USE IN UNAPPROVED INDICATION while taking MYCOPHENILIC ACID?

If you experience product use in unapproved indication while taking MYCOPHENILIC ACID, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages

MYCOPHENILIC ACID Full ProfileAll Drugs Causing PRODUCT USE IN UNAPPROVED INDICATIONAccord Healthcare Inc. Drugs
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.